MRAs Effectively Lower Blood Pressure
Yes, mineralocorticoid receptor antagonists (MRAs) like spironolactone and eplerenone definitively lower blood pressure. The primary goal of MRA therapy in primary aldosteronism is blood pressure control, with spironolactone reducing systolic BP by 40-60 mmHg and achieving BP <140/90 mmHg in approximately 50% of patients on monotherapy 1, 2.
Evidence for Blood Pressure Reduction
Spironolactone
Spironolactone is the most potent MRA for blood pressure lowering. In primary aldosteronism, it reduces systolic BP by 15 mmHg and diastolic BP by 8 mmHg at doses of 25-50 mg/day, with 48% of patients achieving BP <140/90 mmHg 3. At higher doses (50-400 mg/day), reductions reach 40-60 mmHg systolic 2.
In resistant hypertension, spironolactone (25-50 mg/day) reduces home and 24-hour systolic BP by 6.6-8.7 mmHg compared to placebo, with greater efficacy than doxazosin or bisoprolol 4, 5. This makes it the preferred fourth-line agent when triple therapy (ACE inhibitor/ARB + calcium channel blocker + thiazide-like diuretic) fails to control BP 4, 6.
Eplerenone
Eplerenone lowers blood pressure but requires 2-3 times higher doses than spironolactone for equivalent efficacy 2. The FDA-approved indication confirms eplerenone reduces blood pressure and cardiovascular events 7. At doses of 50-200 mg daily, eplerenone produces placebo-subtracted reductions of 6-13 mmHg systolic and 3-7 mmHg diastolic 3, 7.
However, eplerenone at 25 mg daily does not effectively lower BP 6. Doses of 50-200 mg daily (often divided twice daily due to shorter half-life) are required 2, 6. In resistant hypertension trials, eplerenone at 25-100 mg daily failed to reduce home or 24-hour BP compared to placebo 4.
Practical Dosing Algorithm
For Primary Aldosteronism 1:
- Start spironolactone 12.5-25 mg daily (or 50 mg if severe hypokalemia present)
- Titrate by 25-50 mg increments every 8-12 weeks based on BP response
- Target dose: 50-100 mg/day (maximum 400 mg/day)
- Full effect takes up to 3 months
Alternative with eplerenone:
- Start 25 mg twice daily (or 50 mg twice daily if severe disease)
- Titrate by 25-100 mg increments
- Target: 100-300 mg/day in divided doses
For Resistant Hypertension 4, 5:
- Add spironolactone 25-50 mg daily as fourth agent
- Monitor potassium within 2-3 months
- Requires eGFR ≥45 mL/min/1.73 m²
Critical Monitoring Points
Check electrolytes, renal function, and renin at 2-3 months after initiation or dose changes 1. Discontinue potassium supplements at days 2-4 of MRA therapy (potassium normalizes within 3-5 days) 1.
Common reason for apparent non-response: high dietary salt intake 1. Target sodium <85.5 mmol/day (<5 g salt/day) 1.
Important Caveats
Spironolactone causes dose-related gynecomastia: 6.9% at <50 mg/day, 52% at >150 mg/day 3. This typically appears after ≥6 months but can occur as early as 1-2 months 1. Reducing to ≤50 mg/day often resolves symptoms in younger males 1.
Eplerenone avoids anti-androgenic effects but costs more and requires higher doses 8, 3, 8, 3. It has 50% the MR antagonist potency of spironolactone 3.
Use with caution if eGFR <60 mL/min/1.73 m²; avoid if eGFR <30 mL/min/1.73 m² 2, 3, 2, 3. Hyperkalemia risk increases with concurrent ACE inhibitors or ARBs 1.
GFR may decrease initially with MRA therapy—this represents treatment efficacy, not adverse effect 1. The natural course is eventual long-term stability with renal-sparing effects 1.
Comparative Effectiveness
When comparing MRAs head-to-head: spironolactone demonstrates superior BP lowering to eplerenone in most contexts 3. Both agents reduce BP and visceral adipose tissue similarly when titrated appropriately 9. In resistant hypertension, 4-40% of patients cannot tolerate spironolactone due to hyperkalemia or anti-androgenic effects 4, 5, making eplerenone a reasonable alternative despite requiring higher doses.
Amiloride (10-20 mg) is as effective as spironolactone in resistant hypertension when MRAs are not tolerated 4, 5, though it is less efficacious than spironolactone in primary aldosteronism 8.